LoQus23
Cambridge, GB · 15 employees on LinkedIn · 5 known investors
Find your way into LoQus23
327 people in our graph share verified history with the LoQus23 team — schools, employers, funds. One of them is your warm intro.
Itxaso del Palaciounlockedknows Caroline Benn · together at UCL (overlapped)
knows the team · via UCL
×5knows the team · via Pfizer
×5knows the team · via University of Sussex
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research. Founded in 2019 out of the Dementia Discovery Fund, it operates in the biotech and therapeutics sector.
Founders & leadership
DR
David ReynoldsinCo-founder & CEO
CB
Caroline BenninCo-founder & CSOCaroline Benn is co-founder and chief scientific officer of LoQus23 Therapeutics, which develops small-molecule therapeutics targeting DNA damage repair mechanisms for triplet repeat expansion diseases including Huntington's disease and myotonic dystrophy. She has a background in drug discovery research focused on neurodegenerative diseases.
Investors · 5
Novartis Venture FundBasel · $5M – $25M
SV Health InvestorsBoston · $1M – $20M
Dementia Discovery Fundreported · 2 sourcesLondon
Forbionreported · 2 sourcesNaarden
Also in the syndicate · 1
SV Health Investors' Dementia Discovery Fund (DDF)
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AOct 2024
Forbion (lead), Novartis Venture Fund (NVF), SV Health Investors' Dementia Discovery Fund (DDF)
Source ↗ - Undisclosed amountextended seed roundNov 2021
Dementia Discovery Fund, Novartis Venture Fund
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 6
by search overlap
Quralis6 shared keywordsQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Neuron235 shared keywordsNeuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.
Solu5 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Thumbnail for Seragon Pharmaceuticals4 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
Forbion Capital4 shared keywordsA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.
Companies competing with LoQus23 for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does LoQus23 do?
- LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research. Founded in 2019 out of the Dementia Discovery Fund, it operates in the biotech and therapeutics sector.
- Who founded LoQus23?
- LoQus23 was founded by David Reynolds, Caroline Benn.
- Who are LoQus23's investors?
- LoQus23's investors include Novartis Venture Fund, SV Health Investors, Dementia Discovery Fund, Forbion.
- Where is LoQus23 headquartered?
- LoQus23 is headquartered in Cambridge, GB.